Literature DB >> 19586609

Exendin-4 exerts osteogenic actions in insulin-resistant and type 2 diabetic states.

Bernardo Nuche-Berenguer1, Paola Moreno, Sergio Portal-Nuñez, Sonia Dapía, Pedro Esbrit, María L Villanueva-Peñacarrillo.   

Abstract

Poor control of glucose homeostasis accounts for diabetes-related bone loss. Incretins - GLP-1 and GIP - have been proposed to affect bone turnover. GLP-1, apart from its anti-diabetic and other actions, has shown to exert a bone anabolic effect in streptozotocin-induced type 2 diabetic (T2D) and fructose-induced insulin-resistant (IR) rats. Exendin-4 (Ex-4), a peptide of non-mammalian nature, is sharing with GLP-1 part of its structural sequence, and also several glucoregulatory effects in mammals in an even more efficient manner. We have explored the effect of continuous administration (3 days by osmotic pump) of Ex-4 or saline (control) on bone turnover factors and bone structure in T2D and IR rats, compared to N, and the possible interaction of Ex-4 with the Wnt signalling pathway. Blood was taken before and after treatment for plasma measurements; tibiae and femurs were collected for gene expression of bone markers (RT-PCR) and structure (microCT) analysis; we also measured the mRNA levels of LRP5 - an activator of the Wnt pathway - and those of DKK1 and sclerostin (SOST) - both blockers of LRP5 activity. Compared to N-control, plasma glucose and insulin were respectively higher and lower in T2D; osteocalcin (OC) and tartrate-resistant alkaline phosphatase 5b (TRAP5b) were lower; after Ex-4, these turnover markers were further reduced in T2D and IR, while TRAP5b increased in N. Bone OC, osteoprogeterin (OPG) and receptor activator of NF-kB ligand (RANKL) mRNA were lower in T2D and IR; Ex-4 increased OC in all groups and OPG in N and IR, reduced RANKL in N and T2D but increased it in IR; the LRP5/DKK1 and LRP5/SOST mRNA ratios were similarly decreased in T2D, but in IR, the latter ratio was reduced while the former was increased; after Ex-4, both ratios augmented in N, and that of LRP5/DKK1 tended to normalize in T2D and IR. In conclusion, Ex-4 exerts osteogenic effects in T2D and IR models, and interacts with the Wnt pathway to promote bone formation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 19586609     DOI: 10.1016/j.regpep.2009.06.010

Source DB:  PubMed          Journal:  Regul Pept        ISSN: 0167-0115


  38 in total

Review 1.  The hunger games of skeletal metabolism.

Authors:  Natalie K Y Wee; Paul A Baldock
Journal:  Bonekey Rep       Date:  2014-11-12

2.  The effect of dipeptidyl peptidase-IV inhibition on bone in a mouse model of type 2 diabetes.

Authors:  Emily Jane Gallagher; Hui Sun; Caroline Kornhauser; Aviva Tobin-Hess; Sol Epstein; Shoshana Yakar; Derek LeRoith
Journal:  Diabetes Metab Res Rev       Date:  2014-03       Impact factor: 4.876

Review 3.  Diabetes pharmacotherapy and effects on the musculoskeletal system.

Authors:  Evangelia Kalaitzoglou; John L Fowlkes; Iuliana Popescu; Kathryn M Thrailkill
Journal:  Diabetes Metab Res Rev       Date:  2018-12-20       Impact factor: 4.876

4.  The bone-preserving effects of exendin-4 in ovariectomized rats.

Authors:  Han-Xiao Sun; Nan Lu; Dong-Mei Liu; Lin Zhao; Li-Hao Sun; Hong-Yan Zhao; Jian-Min Liu; Bei Tao
Journal:  Endocrine       Date:  2015-06-25       Impact factor: 3.633

5.  The C-terminal fragment of parathyroid hormone-related peptide promotes bone formation in diabetic mice with low-turnover osteopaenia.

Authors:  D Lozano; L Fernández-de-Castro; S Portal-Núñez; A López-Herradón; S Dapía; E Gómez-Barrena; P Esbrit
Journal:  Br J Pharmacol       Date:  2011-03       Impact factor: 8.739

6.  Liraglutide exerts a bone-protective effect in ovariectomized rats with streptozotocin-induced diabetes by inhibiting osteoclastogenesis.

Authors:  Binhong Wen; Lu Zhao; Hongmei Zhao; Xiaochen Wang
Journal:  Exp Ther Med       Date:  2018-04-10       Impact factor: 2.447

7.  [Diabetes and osteoporosis: pathophysiological interactions and clinical importance for geriatric patients].

Authors:  M Lechleitner; K Pils; R Roller-Wirnsberger; E Beubler; R Gasser; P Mrak; F Hoppichler; P Pietschmann
Journal:  Z Gerontol Geriatr       Date:  2013-07       Impact factor: 1.281

8.  Dipeptidyl peptidase-4 inhibitor use is associated with decreased risk of fracture in patients with type 2 diabetes: a population-based cohort study.

Authors:  Wen-Hsuan Hou; Kai-Cheng Chang; Chung-Yi Li; Huang-Tz Ou
Journal:  Br J Clin Pharmacol       Date:  2018-06-29       Impact factor: 4.335

Review 9.  Drugs for type 2 diabetes: role in the regulation of bone metabolism.

Authors:  Edoardo Mannucci; Ilaria Dicembrini
Journal:  Clin Cases Miner Bone Metab       Date:  2015-10-26

Review 10.  Risk of bone fractures associated with glucagon-like peptide-1 receptor agonists' treatment: a meta-analysis of randomized controlled trials.

Authors:  Bin Su; Hui Sheng; Manna Zhang; Le Bu; Peng Yang; Liang Li; Fei Li; Chunjun Sheng; Yuqi Han; Shen Qu; Jiying Wang
Journal:  Endocrine       Date:  2014-07-30       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.